1. Introduction {#sec1}
===============

Epilepsy is a common chronic neurological disorder, which has devastating effects on patients and their families. There are about 50 million epilepsy patients worldwide and the occurrence in developing countries is more than twice that in developed countries \[[@B1]\]. Currently there are more than 20 antiepileptic drugs available for epilepsy patients \[[@B2]\]; however, multidirectional interactions between seizures and the medications are still challenging for treating patients \[[@B3]\]. Exploring the biological alterations of patients may provide insights into the pathology and new targets for treatments.

Large-scale microarray expression strategy has provided greater ease for investigating the underlying mechanisms of epilepsy. Several gene expression profiling studies have been carried out earlier and most of them used the routine variance/regression analysis \[[@B4]--[@B6]\]. However, this procedure cannot remove unaccounted array specific factors, such as certain demographic profiles. Compared with the routine analysis, previous studies \[[@B7], [@B8]\] proposed that partial least squares- (PLS-) based analysis is more robust in proceeding gene expression profile data with higher sensitivity. Therefore, using PLS analysis may provide new understanding of the pathogenesis of epilepsy.

In the current study, to identify truly differentially expressed genes between epilepsy patients and normal controls, we carried out a PLS analysis with two combined data sets from the Gene Expression Omnibus (GEO) database. Gene ontology (GO) enrichment analysis was also carried out for the selected genes to capture the biological relevant signatures. A network constructed by proteins encoded by dysregulated genes was used to identify key molecules among the differentially expressed genes. Our results here may provide new understanding on the pathogenesis of epilepsy.

2. Materials and Methods {#sec2}
========================

2.1. Microarray Data {#sec2.1}
--------------------

Two data sets (GSE4290 and GSE50161) from the GEO (<http://www.ncbi.nlm.nih.gov/geo/>) database, which include 23 epilepsy patients and 13 healthy controls, were used in this study.

The two data sets were both based on the GPL570platform Affymetrix Human Genome U133 Plus 2.0 Array. Detailed information of the samples is listed in [Table 1](#tab1){ref-type="table"}.

2.2. Detection of Differentially Expressed Genes {#sec2.2}
------------------------------------------------

Normalization of raw intensity values was carried out with robust multiarray analysis (RMA) \[[@B9]\]. The resulting log2-transformed expression values of all probes were used for further PLS analysis \[[@B10], [@B11]\], which is a dimension reduction method for modeling without imposing strong assumptions, to estimate the effects for each probe in epilepsy patients. Briefly, NIPALS algorithm \[[@B12]\] was firstly used to obtain PLS latent variables derived from the expression profile; variable importance on the projection (VIP) \[[@B13]\] was then calculated to estimate the effect of the expressed probes on the disease status of the patients. Finally, the empirical distribution of PLS-based VIP was obtained with a permutation procedure (*N* = 10000 times) and false discovered rate (FDR) of each probe was calculated based on the empirical distribution. Probes with FDR value less than 0.05 were selected as differentially expressed genes in this study.

2.3. Enrichment Analysis {#sec2.3}
------------------------

Identified differentially expressed probes were annotated by using the simple omnibus format in text (SOFT) format files. All genes were then mapped to the Gene Ontology database \[[@B14]\], which provides a controlled vocabulary of terms for describing gene product characteristics. Hyper geometric distribution test was carried out to identify GO items enriched with differentially expressed genes.

2.4. Network Analysis {#sec2.4}
---------------------

Most proteins function through interactions with other proteins. Proteins with more interactions with other proteins are supposed to play more important roles in biological processes. To identify key molecules among the differentially expressed genes, we constructed an interaction network with the proteins encoded by selected genes by using the software Cytoscape (V 2.8.3, <http://www.cytoscape.org/>) \[[@B15]\]. Interaction information of the proteins was obtained from the NCBI database (<http://ftp.ncbi.nlm.nih.gov/gene/GeneRIF/>). The number of links (interactions) for each protein was defined as its degree. Proteins with degrees more than 10 were selected as hub molecules in this study.

3. Results {#sec3}
==========

After quality control, two samples (GSM1214938 and GSM1214939) were excluded from subsequent analysis due to aberrant RNA degradation. Thus, 23 epilepsy patients and 11 healthy controls were used in PLS analysis. Sample classification according to the three selected latent variables is illustrated in [Figure 1](#fig1){ref-type="fig"}. After FDR control, a total of 752 genes were identified to be differentially expressed, including 575 depressed and 177 overexpressed genes in patients. The top ten GO items enriched with differentially expressed genes are listed in [Table 2](#tab2){ref-type="table"}. Most of them (60%) are related to the nervous system, including nervous system development (GO:0007399), central nervous system myelin maintenance (GO:0007399), neuroligin clustering (GO:0007399), synapse assembly (GO:0007416), spinal cord motor neuron differentiation (GO:0021522), and glial cell development (GO:0021782).

[Figure 2](#fig2){ref-type="fig"} represents the interaction network of proteins encoded by selected genes. Two proteins, CUL3 and EP300, were identified to be hub molecules, with degrees of 56 and 21, respectively.

4. Discussion {#sec4}
=============

Pathophysiology of epilepsy is highly complex. Gene expression profiling is useful in investigating the underlying mechanism of epilepsy. For the data analysis, creating a suitable model to handle small sample sizes and large number of genes \[[@B7]\] remains challenging. Previous studies \[[@B7], [@B8]\] have demonstrated better performance of the PLS-based method than common variance/regression analysis, which cannot remove hidden biological effects. Here we used PLS analysis to identify differentially expressed genes between epilepsy patients and healthy controls.

As shown in [Figure 1](#fig1){ref-type="fig"}, the selected three latent variables performed well in classification of the samples. GO enrichment analysis of the selected genes revealed the overrepresentation of differentially expressed genes in the nervous system. This is consistent with previous studies. For example, glial cells have been reported to play prominent roles in seizure precipitation and recurrence \[[@B16]\], and the glial cell development was identified to be enriched with dysregulated genes in our study (*P* = 4.18 × 10^−3^). In addition, angiogenesis (GO:0001525) was also found to be overrepresented with dysregulated genes. Dysregulation of angiogenesis may be related to the dysfunction of blood-brain barrier, contributing to epileptogenesis \[[@B17]\]. Signs of angiogenesis were also reported to be corresponding with seizure-induced neuronal death in animal models of familial epilepsy \[[@B18]\]. Our results here further confirmed the involvement of angiogenesis process in the pathogenesis of epilepsy.

According to the network analysis, CUL3 was identified to be a hub molecule with the highest degree ([Figure 2](#fig2){ref-type="fig"}). CUL3 is a core component and scaffold protein of an E3 ubiquitin ligase complex. Previous expression studies have not reported the differential expression of CUL3 in epilepsy patients. However, E3 ubiquitin ligase may affect the synaptic functions in the central nervous system and the stability of kainate receptors, which form a class of glutamate receptors implicated in epilepsy \[[@B19], [@B20]\]. Our results suggested that CUL3 may serve as a potential target in therapeutic studies.

*EP300* is another hub gene with the degree of 21. No report of this gene and epilepsy has been proposed before. However, protein encoded by this gene is a transcriptional coactivator, which stimulates CREB-dependent gene expression. Seizure disorder was reported to be more frequent in Rubinstein-Taybi syndrome patients with CREBBP mutations \[[@B21]\]. In addition, the promoted signaling mechanism of EP300 is important in the neuronal survival process \[[@B22]\] and this gene was related to other neuronal disorders, such as familial Alzheimer\'s disease \[[@B22]\]. Thus, the correlation of this gene and epilepsy pathogenesis may involve the activity of CREB-dependent proteins and further investigation is warranted.

In summary, using two data sets from the GEO database, we carried out PLS-based gene expression analysis to investigate the underlying pathology of epilepsy. Except for processes related to the nervous system, we also identified overrepresentation of dysregulated genes in angiogenesis. Network analysis revealed two hub genes,*CUL3* and*EP300*, which may serve as potential targets in further therapeutic studies. Our results here may provide new understanding for the underlying mechanisms of epilepsy pathogenesis and will offer potential targets for producing new treatments.
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![Sample classification by using the three selected partial least squares (PLS) latent variables.](TSWJ2014-731091.001){#fig1}

![Interaction network constructed with proteins encoded by selected genes. Proteins with more links are shown in bigger size. Proteins shown in red are encoded by overexpressed genes in patients while those in blue are encoded by depressed genes in patients.](TSWJ2014-731091.002){#fig2}

###### 

Characteristics of the expression profile used in this study.

  Accession ID   Description
  -------------- ------------------------------------
  GSM97800       Brain tissue from epilepsy patient
  GSM97803       Brain tissue from epilepsy patient
  GSM97804       Brain tissue from epilepsy patient
  GSM97805       Brain tissue from epilepsy patient
  GSM97807       Brain tissue from epilepsy patient
  GSM97809       Brain tissue from epilepsy patient
  GSM97811       Brain tissue from epilepsy patient
  GSM97812       Brain tissue from epilepsy patient
  GSM97816       Brain tissue from epilepsy patient
  GSM97817       Brain tissue from epilepsy patient
  GSM97820       Brain tissue from epilepsy patient
  GSM97825       Brain tissue from epilepsy patient
  GSM97827       Brain tissue from epilepsy patient
  GSM97828       Brain tissue from epilepsy patient
  GSM97833       Brain tissue from epilepsy patient
  GSM97834       Brain tissue from epilepsy patient
  GSM97840       Brain tissue from epilepsy patient
  GSM97846       Brain tissue from epilepsy patient
  GSM97848       Brain tissue from epilepsy patient
  GSM97849       Brain tissue from epilepsy patient
  GSM97850       Brain tissue from epilepsy patient
  GSM97853       Brain tissue from epilepsy patient
  GSM97855       Brain tissue from epilepsy patient
  GSM1214936     Brain tissue from normal control
  GSM1214937     Brain tissue from normal control
  GSM1214938     Brain tissue from normal control
  GSM1214939     Brain tissue from normal control
  GSM1214940     Brain tissue from normal control
  GSM1214941     Brain tissue from normal control
  GSM1214942     Brain tissue from normal control
  GSM1214943     Brain tissue from normal control
  GSM1214944     Brain tissue from normal control
  GSM1214945     Brain tissue from normal control
  GSM1214946     Brain tissue from normal control
  GSM1214947     Brain tissue from normal control
  GSM1214948     Brain tissue from normal control

###### 

The top 10 GO items enriched with differentially expressed genes.

  GO_id        GO_description                              GO_class   *P* value
  ------------ ------------------------------------------- ---------- --------------
  GO:0007155   Cell adhesion                               Process    3.74*E* − 05
  GO:0072659   Protein localization to plasma membrane     Process    4.75*E* − 05
  GO:0001525   Angiogenesis                                Process    2.64*E* − 04
  GO:0007399   Nervous system development                  Process    9.26*E* − 04
  GO:0032286   Central nervous system myelin maintenance   Process    1.43*E* − 03
  GO:0097118   Neuroligin clustering                       Process    1.43*E* − 03
  GO:0007416   Synapse assembly                            Process    1.59*E* − 03
  GO:0021522   Spinal cord motor neuron differentiation    Process    2.57*E* − 03
  GO:0005509   Calcium ion binding                         Function   4.01*E* − 03
  GO:0021782   Glial cell development                      Process    4.18*E* − 03
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